Using a rhabdomyosarcoma patient-derived xenograft to examine precision medicine approaches and model acquired resistance

导出原文传递

翻译打印收藏纠错

作者： Monsma,D.J. ^[1] ; Cherba,D.M. ^[2] ; Richardson,P.J. ^[3] ; Vance,S. ^[4] ; Rangarajan,S. ^[5] ; Dylewski,D. ; Eugster,E. ; Scott,S.B. ; Beuschel,N.L. ; Davidson,P.J. ; Axtell,R. ; Mitchell,D. ; Lester,E.P. ; Junewick,J.J. ; Webb,C.P. ; Monks,N.R.

作者单位： Van Andel Research Institute, Center for Translational Medicine, Grand Rapids, MI, United States ^[1] NuMedii, Inc., Palo Alto, CA, United States ^[2] Helen DeVos Childrens Hospital, Pediatric Hematology/Oncology, Grand Rapids, MI, United States ^[3] Oncology Care Associates PLLC, Saint Joseph, MI, United States ^[4] Helen DeVos Children's Hospital, Advanced Radiology Services, Michigan State University, Grand ^[5]

关键词 Drug efficacy Drug prediction Gene expression profiling PDX Precision medicine Rhabdomyosarcoma

发布时间 2014-11-16

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交